NO980556D0 - Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus - Google Patents

Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus

Info

Publication number
NO980556D0
NO980556D0 NO980556A NO980556A NO980556D0 NO 980556 D0 NO980556 D0 NO 980556D0 NO 980556 A NO980556 A NO 980556A NO 980556 A NO980556 A NO 980556A NO 980556 D0 NO980556 D0 NO 980556D0
Authority
NO
Norway
Prior art keywords
insulin
patient
procedure
reducing
amount
Prior art date
Application number
NO980556A
Other languages
English (en)
Other versions
NO980556L (no
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO980556D0 publication Critical patent/NO980556D0/no
Publication of NO980556L publication Critical patent/NO980556L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO980556A 1995-08-10 1998-02-09 Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus NO980556L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US209895P 1995-08-10 1995-08-10
PCT/US1996/012430 WO1997005875A2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Publications (2)

Publication Number Publication Date
NO980556D0 true NO980556D0 (no) 1998-02-09
NO980556L NO980556L (no) 1998-02-09

Family

ID=21699238

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980556A NO980556L (no) 1995-08-10 1998-02-09 Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus

Country Status (15)

Country Link
EP (1) EP0851757A2 (no)
JP (1) JPH11510508A (no)
KR (1) KR19990036290A (no)
CN (1) CN1192683A (no)
AU (1) AU724989B2 (no)
BG (1) BG102235A (no)
CA (1) CA2221241A1 (no)
CZ (1) CZ32998A3 (no)
EA (1) EA199800177A1 (no)
HU (1) HUP9802543A2 (no)
IL (1) IL122191A0 (no)
NO (1) NO980556L (no)
NZ (1) NZ313874A (no)
SK (1) SK16498A3 (no)
WO (1) WO1997005875A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
WO1997005875A3 (en) 1997-03-27
NZ313874A (en) 2000-09-29
IL122191A0 (en) 1998-04-05
WO1997005875A2 (en) 1997-02-20
JPH11510508A (ja) 1999-09-14
CZ32998A3 (cs) 1998-10-14
EA199800177A1 (ru) 1998-10-29
AU6641196A (en) 1997-03-05
AU724989B2 (en) 2000-10-05
CA2221241A1 (en) 1997-02-20
HUP9802543A2 (hu) 1999-07-28
NO980556L (no) 1998-02-09
SK16498A3 (en) 1999-03-12
BG102235A (en) 1998-09-30
CN1192683A (zh) 1998-09-09
EP0851757A2 (en) 1998-07-08
KR19990036290A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
CA2024502A1 (en) Dosage form for administering oral hypoglycemic glipizide
ZA845620B (en) Novel insulin derivatives,processes for their preparation and their use,and pharmaceutical agents for the treatment of diabetes mellitus
AU4741790A (en) Syringe adapted to prevent needle sticks
DE69111832D1 (de) Naproxen-Formulierung zur kontrollierten Absorption zur einmal täglichen Anwendung.
AU2847389A (en) Single-use syringe
AU1924795A (en) Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration
FR2623806B1 (fr) Esters d'acides 3,6-dihydro-1,5(2h)-pyrimidinecarboxyliques a action therapeutique
NO980556D0 (no) Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus
CA2113856A1 (en) Antidiabetic Agent
SK42395A3 (en) Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof
AU5352190A (en) Single-use syringe for injections
GB8911818D0 (en) Single-use hypodermic syringe adaptor therefor
AU4967390A (en) Single-use syringe for injections
DE69527137D1 (de) Verwendung eines komplexes kohlenhydrates zur verringerung der hypoglykömie bei diabetes mellitus-patienten
AU4846090A (en) Single-use medical needle
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
DK0785787T3 (da) Anvendelse af 1,5-benzodiazepinderivater til kontrol af mavetømning hos patienter med ikke insulinafhængig diabetes mellitus
ATE124627T1 (de) Diclofenac-natrium enthaltende pharmazeutische zusammensetzung zur topischen anwendung.
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
EP0355591A3 (en) Implantable medicament-dosing device for the injection of a liquid medicament into a living organ
AU3751193A (en) Syringe for medical use with non-reusable automatically disappearing needle
MX9709958A (es) Un metodo para reducir la cantidad de insulina exogena administrada a un paciente que tenga diabetes melitus dependiente de insulina.
USD323030S (en) Medical syringe for administering subcutaneous injections
RU97112627A (ru) Способ коррекции липидных нарушений мембран тромбоцитов у больных сахарным диабетом i типа
SU1624511A1 (ru) Способ моделировани сахарного диабета

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application